Latest Development Pipeline News

Arena REIT reported a robust FY25 with net profit up 42% to $81.5 million, driven by rental growth and property revaluations, while raising FY26 distribution guidance by 5.5%. The Group also announced a CEO succession plan amid sustained portfolio expansion and strong capital management.

Spark New Zealand is selling 75% of its data centre business to Pacific Equity Partners for up to $705 million, aiming to accelerate capacity expansion amid rising cloud and AI demand.

Finbar Group has sold out its $113 million Bel-Air Apartments project well before its anticipated mid-2026 completion, highlighting strong demand for mid-tier apartments in Western Australia.

Island Pharmaceuticals has raised $350,000 through an options exercise by substantial shareholder MWP Partners, reinforcing confidence in its antiviral drug development pipeline.

Dexus Convenience Retail REIT reported steady FY25 results, maintaining near-full occupancy and a strong portfolio valued at $728 million, while advancing key redevelopment projects and sustainability initiatives.

DigiCo Infrastructure REIT’s SYD1 data centre has achieved the highest Australian Government certification for secure data hosting, reinforcing its role in national digital infrastructure.

Dexus Industria REIT has agreed to sell its remaining Brisbane Technology Park assets for $155.5 million, marking a strategic pivot to concentrate solely on industrial properties.

Centuria Industrial REIT (ASX, CIP) reported solid FY25 financial results with robust occupancy and earnings growth, setting the stage for higher distributions and continued development in FY26.

Centuria Industrial REIT reported a solid FY25 with a 2% rise in Funds From Operations and announced a $60 million on-market buy-back to address valuation gaps. The REIT projects further growth in FY26 backed by robust leasing and asset management.

Noxopharm’s Sofra™ technology shows promising results in collaboration with US biotech Tezcat Biosciences, advancing targeted drug delivery for cancer and inflammatory diseases.

Horizon Minerals has executed a binding agreement to acquire the Gordons Dam and adjacent gold projects near its Black Swan processing plant, adding an inferred resource of 20,000 ounces and promising exploration upside.

Imagion Biosystems has raised A$3.5 million through a placement to fund its Phase 2 clinical trial for HER2+ Breast Cancer in the US, marking a significant step in advancing its proprietary MagSense® imaging technology.